α-Synuclein Aggregation in Treatment of Parkinson's Disease

Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.

Novel DNA Aptamers for Parkinson's Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation: Molecular Therapy - Nucleic Acids

Pathological Pathways and Alpha-Synuclein in Parkinson's Disease: A View from the Periphery

Initiation and progression of α-synuclein pathology in Parkinson's disease

α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis - ScienceDirect

Alpha Synuclein in Parkinson's Disease Diagnostics

Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration, Acta Neuropathologica Communications

Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease

Curcumin Interacts with α-Synuclein Condensates To Inhibit Amyloid Aggregation under Phase Separation

HTRF Phospho-A-Synuclein Ser129 aggregation

α-synuclein aggregation assay - Innoprot Parkinson's Disease Models

Current Progress in the Development of Probes for Targeting α-Synuclein Aggregates